HomeMarket NewsPositive News Sends Genfit Stocks Soaring 20% After Hours

Positive News Sends Genfit Stocks Soaring 20% After Hours

Actionable Trade Ideas

always free

Anatomy of human body with liver. 3d illustration

Mohammed Haneefa Nizamudeen

Genfit’s stock (NASDAQ: GNFT) witnessed a remarkable 20% surge in after-hours trading following the release of promising Phase 3 study results for their drug, elafibranor, in the treatment of primary biliary cholangitis (PBC), a rare liver disease.

The groundbreaking data was unveiled at the American Association for the Study of Liver Diseases (AASLD) annual meeting and concurrently published in the prestigious New England Journal of Medicine.

Elafibranor was granted breakthrough therapy designation by the FDA for treating adults with PBC who had an inadequate response to ursodeoxycholic acid (UDCA).

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.